Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | HTT | P42858 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338558 | 0.94 | ALDH1A1 (0.51) | ALDH1A1HTTHPGDGAALMNA | |
| SCHEMBL4048718 | 0.88 | KDM4E (0.62) | ALDH1A1HTTHPGDGAALMNA | |
| SCHEMBL13329200 | 0.86 | ALDH1A1 (0.49) | ALDH1A1HTTHPGDGAALMNA | |
| SCHEMBL13172069 | 0.86 | KDM4E (0.42) | ALDH1A1HTTHPGDGAALMNA | |
| SCHEMBL31647935 | 0.84 | KDM4E (0.62) | ALDH1A1HTTHPGDGAALMNA | |
| SCHEMBL1338304 | 0.83 | KDM4E (0.45) | ALDH1A1HTTHPGDGAALMNA | |
| SCHEMBL1337426 | 0.81 | KDM4E (0.43) | ALDH1A1HTTHPGDGAALMNA | |
| SCHEMBL1338636 | 0.81 | HTT (0.65) | ALDH1A1HTTHPGDGAALMNA | |
| SCHEMBL27847121 | 0.81 | KDM4E (0.43) | ALDH1A1HTTHPGDGAALMNA | |
| SCHEMBL1338468 | 0.81 | KDM4E (0.47) | ALDH1A1HTTHPGDGAALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2226323-A1 | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives | Almirall, S.A. (ES) | 2010-09-08 | — | — | EP | disclosed |
| EP-2226323-A1 | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives | Almirall, S.A. (ES) | 2010-09-08 | — | — | EP | disclosed |
| WO-2010097172-A1 | NEW TETRAHYDROPYRAZOLO[3,4-C]ISOQUINOLIN-5-AMINE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-09-02 | — | — | WO | disclosed |
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MERCK SHARP & DOHME CORP | 2010-05-06 | — | — | US | disclosed |
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MERCK SHARP & DOHME CORP | 2010-05-06 | — | — | US | disclosed |
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | MERCK SHARP & DOHME CORP | 2010-05-06 | — | — | US | disclosed |
| EP-1819710-B1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | ALMIRALL LAB (ES) | 2009-03-11 | — | — | EP | disclosed |
| US-20090029955-A1 | Pyridothienopyrimidine Derivatives | ALMIRALL PRODESFARMA S.A. (ES) | 2009-01-29 | — | — | US | disclosed |
| EP-1819710-A1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | Laboratorios Almirall, S.A. (ES) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006058724-A1 | NEW PYRIDOTHIENOPYRIMIDINE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029955-A1 | Pyridothienopyrimidine Derivatives | PNPO, PDE4A, DPYD | ALDH1A1 391/4885HTT 3871/4885HPGD 35/4885 |
| US-20100113415-A1 | EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER | EPHA4, EPHA1, ERBB4 | ALDH1A1 1835/4885HTT 393/4885HPGD 4444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.